Protein Kinase Inhibitors
eBook - ePub

Protein Kinase Inhibitors

From Discovery to Therapeutics

  1. 830 pages
  2. English
  3. ePUB (mobile friendly)
  4. Available on iOS & Android
eBook - ePub

Protein Kinase Inhibitors

From Discovery to Therapeutics

About this book

Protein Kinase Inhibitors: From Discovery to Therapeutics offers a foundational, pragmatic overview of protein kinases inhibitors and their potential role in disease modulation and treatment. Here, international experts in the field offer an integrated discussion of kinase inhibitor biology, biomarker discovery, and methods for drug design and development. After a brief overview of kinases and kinase inhibitors, subsequent chapters discuss individual kinases that are representative of the wider kinases and kinase families, including their roles in disease pathogenesis, underlying mechanisms, potential inhibitors and their modes of action for therapeutic modulation. Several potential drugs under different stages of clinical trials are discussed, including their relevance to cancer, diabetes, obesity, cardiovascular, neurological, and auto-immune and inflammatory disease, among other disorders. The book also addresses the challenges and opportunities for future kinase inhibitor development. - Provides a thorough overview of kinase inhibitor biology and its role in disease progression and modulation - Examines protein kinase inhibitor drugs in various stages of clinical trials and development - Offers methods and protocols for protein kinase inhibitor research studies and drug design and development - Includes chapter contributions from international leaders in the field

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn more here.
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Protein Kinase Inhibitors by Md. Imtaiyaz Hassan,Saba Noor in PDF and/or ePUB format, as well as other popular books in Biological Sciences & Biochemistry. We have over one million books available in our catalogue for you to explore.

Table of contents

  1. Cover
  2. Front Matter
  3. Table of Contents
  4. Copyright
  5. Contributors
  6. Preface
  7. List of Illustrations
  8. List of Tables
  9. Chapter 1 : Kinase inhibitors: An overview
  10. Chapter 2 : Protein kinase inhibitors and cancer targeted therapy
  11. Chapter 3 : Drug discovery for cancer therapy with special reference to inhibitors of protein kinase pathway
  12. Chapter 4 : An insight on PI3K/AKT/MTOR inhibitors in cancer: Opportunity and translational perspectives
  13. Chapter 5 : Recent advances in the therapeutic development of ERK inhibitors
  14. Chapter 6 : Emerging small-molecule inhibitors of ATM kinase targeting cancer therapy
  15. Chapter 7 : Targeting pyruvate kinase M2 signaling for development of effective cancer therapy
  16. Chapter 8 : Serum and glucocorticoid-regulated kinase 1: A potential target for anticancer therapy
  17. Chapter 9 : Akt inhibitors in cancer therapy
  18. Chapter 10 : Aurora kinase: An emerging potential target in therapeutics
  19. Chapter 11 : The retroactive and future potentials of Aurora kinases in the treatment of cancer
  20. Chapter 12 : Targeting the altered tyrosine kinases in colorectal cancer: From inhibitors to drugs
  21. Chapter 13 : PTEN-induced kinase1 (PINK1): More than just mitochondrial quality control
  22. Chapter 14 : ROCKs as a potential drug target to combat Alzheimer's disease
  23. Chapter 15 : Protein kinase inhibitors from discovery to therapeutics
  24. Chapter 16 : Polo-like kinases: An antimitotic drug target for cancer therapy
  25. Chapter 17 : Src kinase: An attractive therapeutic target for prostate cancer
  26. Chapter 18 : Kinase inhibition in Alzheimer’s disease
  27. Chapter 19 : Therapeutic targeting of glycogen synthase kinase-3: Strategy to address neurodegenerative diseases
  28. Chapter 20 : Microtubule affinity regulating kinase 4: A potential drug target from cancers to neurodegenerative diseases
  29. Chapter 21 : Receptor tyrosine kinase-like orphan receptors ROR1/2: Insights into the mechanism of action, inhibition, and therapeutic potential
  30. Chapter 22 : Therapeutic potential of leucine-rich repeat kinase 2 inhibitors for Parkinson's disease treatment
  31. Chapter 23 : Calcium calmodulin-dependent protein kinase as a potential drug target
  32. Chapter 24 : Therapeutics of platelet-derived growth factor and signaling in different organs
  33. Chapter 25 : EGFRC797S mutation and fourth-generation EGFR tyrosine kinase inhibitors
  34. Chapter 26 : Bacterial histidine kinases as potential antibacterial drug targets
  35. Chapter 27 : Bacterial protein kinases: A target to inhibit the bacterial infections
  36. Chapter 28 : Nanotechnology-based targeted delivery systems for protein kinase inhibitors in Cancer therapy
  37. Index
  38. A